Stock Events

Stock Events

Liquidia 

$68.66
104
+$0.03+0.04% Friday 20:00
+$0.13+0.19%Friday 23:42After hours

Statistics

Day High
68.75
Day Low
68.63
52W High
93.61
52W Low
21.15
Volume
56,202
Avg. Volume
-
Mkt Cap
6.15B
P/E Ratio
458.41
Dividend Yield
-
Dividend
-

Upcoming

Earnings

10NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.49
-0.03
0.42
0.88
Expected EPS
0.8821
Actual EPS
N/A

Financials

-43.53%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
158.32MRevenue
-68.92MNet Income

Analyst Ratings

94.29Average Price Target
The highest estimate is 130.00.
From 7 ratings within the last 6 months. This is not an investment recommendation.
Buy
57%
Hold
29%
Sell
14%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow LQDA. It's not an investment recommendation.
NVIDIA
23
NVDA
Alphabet
23
GOOGL
Amazon
22
AMZN
Microsoft
20
MSFT

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Innoviva
INVA
Mkt Cap1.51B
Innoviva focuses on the development and commercialization of pharmaceuticals, directly competing in the respiratory and pulmonary market similar to Liquidia's focus.
Vertex Pharmaceuticals
VRTX
Mkt Cap137.3B
Vertex Pharmaceuticals is involved in creating therapies for cystic fibrosis, a direct competition to Liquidia's pulmonary disease treatments.
GSK
GSK
Mkt Cap101.78B
GlaxoSmithKline produces a wide range of pharmaceuticals, including treatments for respiratory diseases, directly competing with Liquidia's product offerings.
Astrazeneca
AZN
Mkt Cap252.33B
AstraZeneca is a global biopharmaceutical company focusing on various therapeutic areas, including respiratory diseases, making it a competitor to Liquidia.
Merck
MRK
Mkt Cap366B
Merck & Co., Inc. offers a broad portfolio of drugs, including treatments for respiratory conditions, competing in the same space as Liquidia.
Pfizer
PFE
Mkt Cap159.36B
Pfizer develops and manufactures drugs and vaccines, including for respiratory diseases, positioning it as a competitor to Liquidia.
Biogen
BIIB
Mkt Cap32.28B
Biogen focuses on advanced therapies for serious diseases, including pulmonary conditions, making it a competitor in the same therapeutic area as Liquidia.
Regeneron Pharmaceuticals
REGN
Mkt Cap81.77B
Regeneron Pharmaceuticals is known for its innovative treatments in several areas, including respiratory diseases, competing with Liquidia's developments.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap42.46B
Teva Pharmaceutical Industries specializes in generic and specialty medicines, including for respiratory conditions, making it a competitor to Liquidia.
Novartis
NVS
Mkt Cap292.35B
Novartis focuses on a wide range of healthcare areas, including respiratory diseases, directly competing with Liquidia's therapeutic focus.

About

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.
Show more...
CEO
Roger A. Jeffs
Employees
216
Country
United States
ISIN
US53635D2027
WKN
000A2JRNS

Listings

MU
DE
LT4.MU
STU
DE
LT4.STU
XNAS
US
LQDA
F
DE
LT4.F

0 Comments

Share your thoughts

FAQ

What is Liquidia stock price today?▼
The current price of LQDA is $68.66 USD — it has increased by +0.04% in the past 24 hours. Watch Liquidia stock price performance more closely on the chart.
What is Liquidia stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Liquidia stocks are traded under the ticker LQDA.
Is Liquidia stock price growing?▼
LQDA stock has risen by +1.43% compared to the previous week, the month change is a -23.22% fall, over the last year Liquidia has showed a +137.99% increase.
What is Liquidia market cap?▼
Today Liquidia has the market capitalization of 6.15B
When is the next Liquidia earnings date?▼
Liquidia is going to release the next earnings report on November 10, 2026.
What were Liquidia earnings last quarter?▼
LQDA earnings for the last quarter are 0.74 USD per share, whereas the estimation was 0.76 USD resulting in a -2.34% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Liquidia revenue for the last year?▼
Liquidia revenue for the last year amounts to 158.32M USD.
What is Liquidia net income for the last year?▼
LQDA net income for the last year is -68.92M USD.
How many employees does Liquidia have?▼
As of September 06, 2026, the company has 216 employees.
In which sector is Liquidia located?▼
Liquidia operates in the Health & Wellness sector.
When did Liquidia complete a stock split?▼
Liquidia has not had any recent stock splits.
Where is Liquidia headquartered?▼
Liquidia is headquartered in MORRISVILLE, United States.